These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 19505424)

  • 21. L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure.
    Rose C; Michalak A; Rao KV; Quack G; Kircheis G; Butterworth RF
    Hepatology; 1999 Sep; 30(3):636-40. PubMed ID: 10462368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis.
    Jiang Q; Jiang XH; Zheng MH; Chen YP
    J Gastroenterol Hepatol; 2009 Jan; 24(1):9-14. PubMed ID: 18823442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials.
    He Q; Mao C; Chen Z; Zeng Y; Deng Y; Hu R
    Arab J Gastroenterol; 2024 May; 25(2):84-92. PubMed ID: 38403493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possibilities of therapeutic correction of hyperammonemia and minimal hepatic encephalopathy in patients with chronic hepatitis C at the pre-cirrhotic stage.
    Buyeverov AO; Bogomolov PO; Mayev IV; Matsievich MV; Uvarova OV
    Ter Arkh; 2019 Mar; 91(2):52-58. PubMed ID: 31094172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway.
    Kristiansen RG; Rose CF; Fuskevåg OM; Mæhre H; Revhaug A; Jalan R; Ytrebø LM
    Am J Physiol Gastrointest Liver Physiol; 2014 Nov; 307(10):G1024-31. PubMed ID: 25258408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of arterial ammonia for complications and outcome in acute liver failure.
    Bhatia V; Singh R; Acharya SK
    Gut; 2006 Jan; 55(1):98-104. PubMed ID: 16024550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.
    Mittal VV; Sharma BC; Sharma P; Sarin SK
    Eur J Gastroenterol Hepatol; 2011 Aug; 23(8):725-32. PubMed ID: 21646910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine.
    Garrido M; Skorucak J; Raduazzo D; Turco M; Spinelli G; Angeli P; Amodio P; Achermann P; Montagnese S
    Metab Brain Dis; 2016 Aug; 31(4):965-74. PubMed ID: 27193025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute liver failure-induced death of rats is delayed or prevented by blocking NMDA receptors in brain.
    Cauli O; Rodrigo R; Boix J; Piedrafita B; Agusti A; Felipo V
    Am J Physiol Gastrointest Liver Physiol; 2008 Sep; 295(3):G503-11. PubMed ID: 18599589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.
    Rice TW; Wheeler AP; Bernard GR; Vincent JL; Angus DC; Aikawa N; Demeyer I; Sainati S; Amlot N; Cao C; Ii M; Matsuda H; Mouri K; Cohen J
    Crit Care Med; 2010 Aug; 38(8):1685-94. PubMed ID: 20562702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
    Butterworth RF; McPhail MJW
    Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs.
    Ahn JO; Li Q; Lee YH; Han SM; Hwang CY; Youn HY; Chung JY
    J Vet Sci; 2016 Sep; 17(3):431-3. PubMed ID: 26726023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Butterworth RF; Kircheis G; Hilger N; McPhail MJW
    J Clin Exp Hepatol; 2018 Sep; 8(3):301-313. PubMed ID: 30302048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Physiological functions of L-ornithine and L-aspartate in the body and the efficacy of administration of L-ornithine-L-aspartate in conditions of relative deficiency].
    Sikorska H; Cianciara J; Wiercińska-Drapało A
    Pol Merkur Lekarski; 2010 Jun; 28(168):490-5. PubMed ID: 20642112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of zinc on liver cirrhosis with hyperammonemia: a preliminary randomized, placebo-controlled double-blind trial.
    Katayama K; Saito M; Kawaguchi T; Endo R; Sawara K; Nishiguchi S; Kato A; Kohgo H; Suzuki K; Sakaida I; Ueno Y; Habu D; Ito T; Moriwaki H; Suzuki K
    Nutrition; 2014; 30(11-12):1409-14. PubMed ID: 25280421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: A randomized, double-blind, placebo-controlled trial.
    Alvares-da-Silva MR; de Araujo A; Vicenzi JR; da Silva GV; Oliveira FB; Schacher F; Oliboni L; Magnus A; Kruel LP; Prieb R; Fernandes LN
    Hepatol Res; 2014 Sep; 44(9):956-63. PubMed ID: 24033861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Critical analysis of studies evaluating the efficacy of infusion of L-ornithine L-aspartate in clinical hepatic encephalopathy in patients with liver failure.
    Pérez Hernández JL; Higuera de la Tijera F; Serralde-Zúñiga AE; Abdo Francis JM
    Ann Hepatol; 2011 Jun; 10 Suppl 2():S66-9. PubMed ID: 22228885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishment of hyperammonemia mode in yellow catfish and the mitigation of exogenous L-ornithine-L-aspartate.
    Zhang M; Fan Y; Jiang H; Shao J; Li M
    Dev Comp Immunol; 2022 Oct; 135():104487. PubMed ID: 35803415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of hyperammonemia in liver failure: a tale of two enzymes.
    Jalan R; Lee WM
    Gastroenterology; 2009 Jun; 136(7):2048-51. PubMed ID: 19409290
    [No Abstract]   [Full Text] [Related]  

  • 40. L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle.
    Butterworth RF
    Can J Gastroenterol Hepatol; 2019; 2019():8182195. PubMed ID: 31183339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.